Bristol-Myers Squibb (NYSE:BMY) Short Interest Update

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) was the recipient of a significant drop in short interest during the month of March. As of March 31st, there was short interest totalling 35,120,000 shares, a drop of 5.7% from the March 15th total of 37,250,000 shares. Currently, 1.7% of the company's shares are short sold. Based on an average trading volume of 16,170,000 shares, the days-to-cover ratio is presently 2.2 days.

Bristol-Myers Squibb Stock Down 0.5 %

Bristol-Myers Squibb stock traded down $0.24 during midday trading on Tuesday, hitting $48.27. The stock had a trading volume of 11,931,092 shares, compared to its average volume of 15,903,355. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24. The stock has a market cap of $97.83 billion, a P/E ratio of 12.51, a P/E/G ratio of 1.78 and a beta of 0.39. Bristol-Myers Squibb has a 12 month low of $47.58 and a 12 month high of $70.93. The business has a fifty day moving average price of $51.27 and a 200 day moving average price of $51.62.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.55 by $0.15. The firm had revenue of $11.48 billion during the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. Bristol-Myers Squibb's quarterly revenue was up .6% on a year-over-year basis. During the same period in the previous year, the company earned $1.82 earnings per share. Research analysts predict that Bristol-Myers Squibb will post 5.41 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 4.97%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb's dividend payout ratio is currently 62.18%.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Wells Fargo & Company reduced their price objective on Bristol-Myers Squibb from $58.00 to $51.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 6th. Societe Generale cut Bristol-Myers Squibb from a "buy" rating to a "hold" rating in a research note on Monday, March 11th. StockNews.com cut Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Monday. Bank of America cut Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Finally, William Blair restated a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $61.12.

Institutional Trading of Bristol-Myers Squibb

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. True Wealth Design LLC bought a new position in Bristol-Myers Squibb during the 4th quarter valued at $26,000. Coppell Advisory Solutions Corp. purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at $31,000. Coppell Advisory Solutions LLC purchased a new stake in shares of Bristol-Myers Squibb during the second quarter worth $28,000. Live Oak Investment Partners purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $33,000. Finally, OFI Invest Asset Management purchased a new stake in shares of Bristol-Myers Squibb during the third quarter worth $25,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.